Krystal Biotech price target raised to $215 from $206 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $215 from $206 and keeps a Neutral rating on the ...
Krystal Biotech sees non-GAAP R&D and SG&A expense $150.0M-$175.0M
EST Krystal Biotech (KRYS) sees non-GAAP R&D and SG&A expense $150.0M-$175.0M Discover the Best Stocks and Maximize Your ...